- Home
- FEDU vs SNTI Comparison
FEDU vs SNTI Comparison
Compare FEDU & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEDU
- SNTI
- Stock Information
- Founded
- FEDU 2007
- SNTI 2016
- Country
- FEDU China
- SNTI United States
- Employees
- FEDU 190
- SNTI N/A
- Industry
- FEDU
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- FEDU
- SNTI Health Care
- Exchange
- FEDU NYSE
- SNTI Nasdaq
- Market Cap
- FEDU 22.2M
- SNTI 19.1M
- IPO Year
- FEDU 2017
- SNTI N/A
- Fundamental
- Price
- FEDU $10.49
- SNTI $4.67
- Analyst Decision
- FEDU
- SNTI Strong Buy
- Analyst Count
- FEDU 0
- SNTI 1
- Target Price
- FEDU N/A
- SNTI $12.00
- AVG Volume (30 Days)
- FEDU 4.9K
- SNTI 115.8K
- Earning Date
- FEDU 12-20-2024
- SNTI 11-14-2024
- Dividend Yield
- FEDU 21.93%
- SNTI N/A
- EPS Growth
- FEDU N/A
- SNTI N/A
- EPS
- FEDU 0.12
- SNTI N/A
- Revenue
- FEDU $27,971,139.00
- SNTI N/A
- Revenue This Year
- FEDU N/A
- SNTI $11.52
- Revenue Next Year
- FEDU N/A
- SNTI $78.57
- P/E Ratio
- FEDU $88.02
- SNTI N/A
- Revenue Growth
- FEDU 141.14
- SNTI N/A
- 52 Week Low
- FEDU $7.41
- SNTI $1.52
- 52 Week High
- FEDU $22.70
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- FEDU 48.38
- SNTI 56.65
- Support Level
- FEDU $10.15
- SNTI $3.72
- Resistance Level
- FEDU $10.88
- SNTI $4.93
- Average True Range (ATR)
- FEDU 0.59
- SNTI 0.46
- MACD
- FEDU 0.10
- SNTI 0.01
- Stochastic Oscillator
- FEDU 63.68
- SNTI 81.82
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.